For research use only. Not for therapeutic Use.
JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma[1].
JNJ-49095397 (RV568) (1 pg-1 μg/mL; 4 h) inhibits LPS-induced CXCL8 release in PBMCs and d-U937 cells[1].
JNJ-49095397 (1 μg-1 g/mL; 4 h) inhibits TNFα-induced interleukin (IL)-6 and CXCL8 release in a concentration-dependent manner[1].
JNJ-49095397 (RV568) (1-20 μg/mouse; intratracheal; once) shows anti-inflammatory activities in LPS-induced neutrophil accumulation mouse model[1].
Catalog Number | I042033 |
CAS Number | 1220626-82-3 |
Synonyms | N-[4-[[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxymethyl]pyridin-2-yl]-2-methoxyacetamide |
Molecular Formula | C34H36N6O4 |
Purity | ≥95% |
InChI | InChI=1S/C34H36N6O4/c1-22-10-12-24(13-11-22)40-31(19-29(39-40)34(2,3)4)38-33(42)36-27-14-15-28(26-9-7-6-8-25(26)27)44-20-23-16-17-35-30(18-23)37-32(41)21-43-5/h6-19H,20-21H2,1-5H3,(H,35,37,41)(H2,36,38,42) |
InChIKey | RTDCVLCTBQDLBW-UHFFFAOYSA-N |
SMILES | CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCC5=CC(=NC=C5)NC(=O)COC |
Reference | [1]. Charron CE, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017 Oct 26;50(4):1700188. |